0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Anthracycline-Induced Cardiotoxicity

Kesavan Shan, MD; A. Michael Lincoff, MD; and James B. Young, MD
[+] Article and Author Information

From The Cleveland Clinic Foundation, Cleveland, Ohio. Requests for Reprints: A. Michael Lincoff, MD, Director, Experimental Interventional Laboratory, Department of Cardiology, F25, The Cleveland Clinic Foundation 9500 Euclid Avenue, Cleveland, OH 44195. Current Author Addresses: Dr. Shan: Baylor College of Medicine, Section of Cardiology, 6550 Fannin MS SM 677, Houston, TX 77030. Drs Lincoff and Young: Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Clevelane, OH 44195.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1996;125(1):47-58. doi:10.7326/0003-4819-125-1-199607010-00008
Text Size: A A A

Purpose: To review the current understanding of the clinical significance, detection, pathogenesis, and prevention of anthracycline-induced cardiotoxicity.

Data Sources: A MEDLINE search of the English-language medical literature and a manual search of the bibliographies of relevant articles, including abstracts from national cardiology meetings.

Study Selection: Pertinent clinical and experimental studies addressing the clinical relevance, pathogenesis, detection, and prevention of anthracycline cardiotoxicity were selected from peer-reviewed journals without judgments about study design. A total of 137 original studies and 9 other articles were chosen.

Data Extraction: Data quality and validity were assessed by each author independently. Statistical analysis of combined data was inappropriate given the differences in patient selection, testing, and follow-up in the available studies.

Data Synthesis: Anthracycline-induced cardiotoxicity limits effective cancer chemotherapy by causing early cardiomyopathy, and it can produce late-onset ventricular dysfunction years after treatment has ceased. Detection of subclinical anthracycline-induced cardiomyopathy through resting left ventricular ejection fraction or echocardiographic fractional shortening is suboptimal. Conventional doses of anthracycline often lead to permanent myocardial damage and reduced functional reserve. Underlying pathogenetic mechanisms may include free-radical-mediated myocyte damage, adrenergic dysfunction, intracellular calcium overload, and the release of cardiotoxic cytokines. Dexrazoxane is the only cardioprotectant clinically approved for use against anthracyclines, and it was only recently introduced for selected patients with breast cancer who are receiving anthracycline therapy.

Conclusions: A rapidly growing number of persons, including an alarming fraction of the 150 000 or more adults in the United States who have survived childhood cancer, will have substantial morbidity and mortality because of anthracycline-related cardiac disease. The development of effective protection against anthracycline-induced cardiotoxicity will probably have a significant effect on the overall survival of these patients.

Figures

Grahic Jump Location
Figure 1. Reproduced from Von Hoff and colleagues with permission of .
Cumulative probability of developing doxorubicin-induced congestive heart failure (CHF) plotted against total cumulative dose of doxorubicin in all patients receiving the drug (3941 patients; 88 cases of congestive heart failure).[6]Annals of Internal Medicine
Grahic Jump Location
Grahic Jump Location
Figure 2. Light microscopy. Section of left ventricle from a 57-year-old woman with adriamycin-induced cardiomyopathy showing marked myofibril loss and vacuolar degeneration ( ). (Hematoxylin and eosin stain. Original magnification, × 400). Electron microscopy. Cardiac myocyte showing adriamycin-induced cardiotoxicity with extensive loss of myofilaments (large arrows). Unaffected myocytes are shown in lower left. Small arrow denotes normal myocyte. (Original magnification, × 2800).
Changes characteristic of adriamycin-induced cardiotoxicity. Top.arrowBottom.
Grahic Jump Location
Grahic Jump Location
Figure 3. Percentage of patients with abnormal fractional shortening at long-term follow-up over time after completion of therapy. Adapted from Steinherz and colleagues with permission of The Journal of the American Medical Association. White bars = mild reduction in fractional shortening (25% to 28%); striped bars = moderate reduction in fractional shortening (21% to 24%); black bars = severe reduction in fractional shortening (≤ 20%).
Late-onset ventricular dysfunction over time.[16]
Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)